UAB 1430 - A Phase II Trial of Neoadjuvant PD 0332991, a Cyclin-Dependent Kinase (Cdk) 4/6 inhibitor, in Combination with Anastrozole in Women with Clinical Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Grant

Date/time Interval

  • August 5, 2019 - August 17, 2021
  • Awarded By

    Total Award Amount

  • 21172.00
  • Direct Costs

  • 16859.00
  • Sponsor Award Id

  • Contributor

  • Carolina Salvador M.D.   Principal Investigator  
  • Erica Stringer-Reasor M.D.   Investigator